

26 Jan 2021 | News

QUOTED. 26 January 2021. Jon Otterstatter.

by

Boston Scientific's purchase of Preventice is the fourth major acquisition in the remote monitoring market in the last five weeks, and drew praise from Preventice CEO Jon Otterstatter.

“Boston Scientific has been a key investor in Preventice for more than five years and we believe the company has the commercial reach, diagnostics expertise and operational infrastructure to bring these advanced monitoring technologies to more patients worldwide.” – Jon Otterstatter, CEO, Preventice

- Find out more: [Boston Scientific Bets Big On Monitoring; Buys Preventice For Up To \\$1.25Bn](#)

[Click here](#) for a free trial of *Medtech Insight*